nogrЭкспериментальная и клиническая гастроэнтерологияExperimental and Clinical Gastroenterology1682-8658«Global Media Technologies»nogr-236Research ArticleКЛИНИЧЕСКАЯ ГАСТРОЭНТЕРОЛОГИЯCLINICAL GASTROENTEROLOGYОСОБЕННОСТИ КЛИНИЧЕСКОГО ТЕЧЕНИЯ ВИРУСНОГО ГЕПАТИТА С У ДЕТЕЙ С РАЗЛИЧНЫМИ ВАРИАНТАМИ ПОЛИМОРФИЗМА ГЕНА IL28BTHE CLINICAL COURSE OF HEPATITIS C IN CHILDREN WITH DIFFERENT VARIANTS OF THE GENE POLYMORPHISM IL28BМатинянИ. А.MatinyanI. A.demkina_ira@mail.ruСенцоваТ. Б.SentsovaT. B.noemail@neicon.ruВорожкоИ. В.VorozhkoI. V.noemail@neicon.ruЧернякО. О.ChernyakO. O.noemail@neicon.ruСтроковаТ. В.StrokovaT. V.noemail@neicon.ruГаппаровМ. М.GapparovM. M.noemail@neicon.ruФГБУН «ФИЦ питания и биотехнологии»РоссияFederal Research Centre of Nutrition and BiotechnologyRussian FederationГБОУ ВПО РНИМУ им. Н.И. Пирогова Минздрава РоссииРоссияPirogov Russian National Research Medical University of Ministry of Healthcare of the Russian FederationRussian Federation201620072016075255Copyright © Матинян И.А., Сенцова Т.Б., Ворожко И.В., Черняк О.О., Строкова Т.В., Гаппаров М.М., 20162016Матинян И.А., Сенцова Т.Б., Ворожко И.В., Черняк О.О., Строкова Т.В., Гаппаров М.М.Matinyan I.A., Sentsova T.B., Vorozhko I.V., Chernyak O.O., Strokova T.V., Gapparov M.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.nogr.org/jour/article/view/236

Целью исследования является изучение особенностей клинического течения вирусного гепатита С у детей с различными вариантами полиморфизма гена IL-28B. Материалы и методы. Под наблюдением находилось 94 ребенка (46 девочек и 48 мальчиков) с хроническим гепатитом С (ХГС) в возрасте от 3 до 17 лет (средний возраст 10 лет). Выявлены достоверные различия распределения частот аллелей у детей с ХГС и в популяции. У детей с ХГС достоверно повышена частота встречаемости аллеля Т в локусе гена IL-28B rs12979860 С>T, что дает возможность рассматривать его в качестве предиктора неэффективности противовирусной терапии. Результаты. При анализе частоты встречаемости полиморфного варианта Т>G [rs8099917] гена IL-28B у детей с ХГС и у здоровых детей не выявлено различий в отношении распределения аллелей. Заключение. Персонифицированный подход к назначению противовирусной терапии ХГС у детей заключается в проведении генетических исследований, позволяющих на предсказательной основе определить особенности течения ХГС у детей на фоне проводимого лечения.

Aim of investigation. The aim of the research is to study the clinical course of hepatitis C in children with different variants of the gene polymorphism of IL-28B. Materials and methods. We observed 94 children (46 girls and 48 boys) with chronic hepatitis C (CHC) in age from 3 to 17 years (mean age 10 years). There were significant differences in the distribution of allele frequencies in children with chronic hepatitis C and in the population. In children with chronic hepatitis C significantly increased the incidence of the T allele at the locus of the gene IL-28B rs12979860 C>T, which makes it possible to consider it as a predictor of antiviral therapy ineffective. Results. When analyzing the frequency of occurrence of a polymorphic variant T>G [rs8099917] IL-28B gene in children with chronic hepatitis C and healthy children revealed no differences in the distribution of alleles. Conclusion. Personalized approach to the appointment of HCV antiviral therapy in children is to carry out genetic studies to determine on the basis of predictive features of the course of HCV in children during the treatment.

хронический гепатит Сген ИЛ-28Вполиморфизмпротивовирусная терапияпегилированный интерферонрибавиринchronic hepatitis Cgen IL28Bpolymorphismantiviral therapyPEGylated interferonribavirinReferencesSuzuki M, Tajiri H. Peginterferon Therapy in Children with Chronic Hepatitis C: A Nationwide, Multi-center Study in Japan, 2004-2013. J Pediatr Gastroenterol Nutr. 2016 Jan 27.Suzuki M, Tajiri H. Peginterferon Therapy in Children with Chronic Hepatitis C: A Nationwide, Multi-center Study in Japan, 2004-2013. J Pediatr Gastroenterol Nutr. 2016 Jan 27.Robinson MW, Hughes J. Tracking TCRβ sequence clonotype expansions during antiviral therapy using high-throughput sequencing of the hypervariable region. Front Immunol. 2016 Apr 5;7:131.Robinson MW, Hughes J. Tracking TCRβ sequence clonotype expansions during antiviral therapy using high-throughput sequencing of the hypervariable region. Front Immunol. 2016 Apr 5;7:131.Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009;41:1105-1109.Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009;41:1105-1109.Kelly C, Klenerman P, Barnes E. Interferon lambdas: the next cytokine storm. [PubMed].Kelly C, Klenerman P, Barnes E. Interferon lambdas: the next cytokine storm. [PubMed].Stättermayer AF, Stauber R, Hofer H, et al. Impact of IL28B genotype on the early and sustained virologic response in treatment-naive patients with chronic hepatitis C. Clin Gastroenterol Hepatol.2011;9:344-350.Stättermayer AF, Stauber R, Hofer H, et al. Impact of IL28B genotype on the early and sustained virologic response in treatment-naive patients with chronic hepatitis C. Clin Gastroenterol Hepatol.2011;9:344-350.Rauch A., Kutalik Z., Descombes P. et al. Genetic variation in IL28 B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology. 2010. Vol. 138, № 4. P. 1338-1345Rauch A., Kutalik Z., Descombes P. et al. Genetic variation in IL28 B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology. 2010. Vol. 138, № 4. P. 1338-1345Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461:399-401.Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461:399-401.Gale M, Jr, Foy EM. Evasion of intracellular host defence by hepatitis C virus. Nature. 2005;436:939-945.Gale M, Jr, Foy EM. Evasion of intracellular host defence by hepatitis C virus. Nature. 2005;436:939-945.Симанкова Т. В., Гармаш И. В., Аришева О. С. и др. Генетический полиморфизм гена ИЛ-28B как предиктор успеха ПВТ хронического гепатита С. Клиническая фармакология и терапия. 2012. Т. 21. No 1. С. 1-6.Симанкова Т. В., Гармаш И. В., Аришева О. С. и др. Генетический полиморфизм гена ИЛ-28B как предиктор успеха ПВТ хронического гепатита С. Клиническая фармакология и терапия. 2012. Т. 21. No 1. С. 1-6.Moghaddam A., Melum E., Reinton N. et al. Hepatology. 2011. V. 53. P. 746-754.Moghaddam A., Melum E., Reinton N. et al. Hepatology. 2011. V. 53. P. 746-754.Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975-982.Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975-982.Hadziyannis SJ, Sette H, Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004; 140:346-355.Hadziyannis SJ, Sette H, Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004; 140:346-355.Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461:399-401.Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461:399-401.David L. Thomas, M. D. Predicting the Response to the Treatment of Hepatitis C Virus Infection. Clinical Liver Disease, Vol. 1, No. 2, April 2012: 46-48.David L. Thomas, M. D. Predicting the Response to the Treatment of Hepatitis C Virus Infection. Clinical Liver Disease, Vol. 1, No. 2, April 2012: 46-48.A. J. Thompson. Genetic factors and hepatitis C virus infection. Gastroenterology. 2012. Vol. 142. P. 1335-1339.A. J. Thompson. Genetic factors and hepatitis C virus infection. Gastroenterology. 2012. Vol. 142. P. 1335-1339.Stevan A. Gonzalez, Emmet B. Keeffe. IL-28B As a Predictor of Sustained Virologic Response in Patients with Chronic Hepatitis C Virus Infection. Gastroenterol Hepatol (N Y). 2011 Jun; 7 (6): 366-373.Stevan A. Gonzalez, Emmet B. Keeffe. IL-28B As a Predictor of Sustained Virologic Response in Patients with Chronic Hepatitis C Virus Infection. Gastroenterol Hepatol (N Y). 2011 Jun; 7 (6): 366-373.

The authors declare that there are no conflicts of interest present.